CSL CSL Limited

By Chris Wack

Seqirus said Tuesday that the U.S. Food and Drug Administration has approved Afluria Quadrivalent, an influenza vaccine, for use in people six months of age and older.

According to the Summit-N.J.-based Seqirus, the approval also applies to the trivalent formulation of Afluria.

Afluria Quadrivalent was first approved in the U.S. in August 2016 for adults aged 18 years and above, and helps protect against two influenza A strain viruses and two B strain viruses.

Afluria Quadrivalent is available in the U.S. for the 2018-2019 influenza season in prefilled syringes as well as multidose vials.

Seqirus is a unit of Melbourne, Australia-based CSL Limited.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

October 23, 2018 08:43 ET (12:43 GMT)

CSL (ASX:CSL)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024

CSL (ASX:CSL)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024